Maximal testosterone suppression in prostate cancer - Free vs total testosterone

Kyle O. Rove, E. David Crawford, Massimo Perachino, Juan Morote, Laurence Klotz, Paul H. Lange, Gerald L. Andriole, Alvin M. Matsumoto, Samir S. Taneja, Mario A. Eisenberger, Leonardo O. Reis

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes. © 2014 Elsevier Inc. All Rights Reserved.
Original languageEnglish
Pages (from-to)1217-1222
JournalUrology
Volume83
Issue number6
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint Dive into the research topics of 'Maximal testosterone suppression in prostate cancer - Free vs total testosterone'. Together they form a unique fingerprint.

Cite this